A Phase I Study of the Vascular Disrupting Combretastatin, OXi4503, in Patients with Relapsed and Refractory Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS)

Christopher R. Cogle, John R. Wingard, Leslie Pettiford et al.|Blood|2012

Cited by 0